PMID- 10779157
OWN - NLM
STAT- MEDLINE
DCOM- 20000630
LR  - 20071114
IS  - 1043-0342 (Print)
IS  - 1043-0342 (Linking)
VI  - 11
IP  - 6
DP  - 2000 Apr 10
TI  - Gene-modified dendritic cells for use in tumor vaccines.
PG  - 797-806
AB  - Dendritic cells (DCs) are potent antigen-presenting cells capable of priming 
      activation of naive T cells. Because of their immunostimulatory capacity, 
      immunization with DCs presenting tumor antigens has been proposed as a treatment 
      regimen for cancer. The results from translational research studies and early 
      clinical trials point to the need for improvement of DC-based tumor vaccines 
      before they become a more broadly applicable treatment modality. In this regard, 
      studies suggest that genetic modification of DCs to express tumor antigens and/or 
      immunomodulatory proteins may improve their capacity to promote an antitumor 
      response. Because the DC phenotype is relatively unstable, nonperturbing methods 
      of gene transfer must be employed that do not compromise viability or 
      immunostimulatory capacity. DCs expressing transgenes encoding tumor antigens 
      have been shown to be more potent primers of antitumor immunity both in vitro and 
      in animal models of disease; in some measures of immune priming, gene-modified 
      DCs exceeded their soluble antigen-pulsed counterparts. Cytokine gene 
      modification of DCs has improved their capacity to prime tumor antigen-specific T 
      cell responses and promote antitumor immunity in vivo. Here, we review the 
      current status of gene-modified DCs in both human and murine studies. Although 
      successful results have been obtained to date in experimental systems, we discuss 
      potential problems that have already arisen and may yet be encountered before 
      gene-modified DCs are more widely applicable for use in human clinical trials.
FAU - Kirk, C J
AU  - Kirk CJ
AD  - Department of Surgery, Tumor Immunology Program of the Comprehensive Cancer 
      Center, University of Michigan Medical Center, Ann Arbor 48109-0666, USA. 
      ckirk@umich.edu
FAU - Mule, J J
AU  - Mule JJ
LA  - eng
GR  - 1 R01 CA71669/CA/NCI NIH HHS/United States
GR  - 5 P01 CA59327/CA/NCI NIH HHS/United States
GR  - M01-RR00042/RR/NCRR NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Research Support, U.S. Gov't, P.H.S.
PT  - Review
PL  - United States
TA  - Hum Gene Ther
JT  - Human gene therapy
JID - 9008950
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Cancer Vaccines)
RN  - 0 (Cytokines)
RN  - 0 (DNA, Viral)
SB  - IM
MH  - Animals
MH  - Antigens, Neoplasm/genetics/metabolism
MH  - Cancer Vaccines/*genetics/immunology
MH  - Cytokines/genetics
MH  - DNA, Viral/genetics
MH  - *Dendritic Cells/cytology/metabolism
MH  - *Gene Transfer Techniques
MH  - Genetic Vectors
MH  - Humans
MH  - Mice
RF  - 68
EDAT- 2000/04/25 09:00
MHDA- 2000/07/08 11:00
CRDT- 2000/04/25 09:00
PHST- 2000/04/25 09:00 [pubmed]
PHST- 2000/07/08 11:00 [medline]
PHST- 2000/04/25 09:00 [entrez]
AID - 10.1089/10430340050015419 [doi]
PST - ppublish
SO  - Hum Gene Ther. 2000 Apr 10;11(6):797-806. doi: 10.1089/10430340050015419.